
Opinion|Videos|February 1, 2025
One Institution’s Evidence-Based Approach to Adopting Biosimilars
A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please describe the process your institution uses to review biosimilars as potential additions to the formulary.
- What priorities were identified by your institution for the purposes of operationalizing the use of biosimilars?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























